TY  - JOUR
TI  - Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
AB  - Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.
AU  - KULA, Serdar
AU  - İNCEDERE, FATMA
AU  - TOKGÖZ, Semiha
AU  - Tunaoğlu, Fatma Sedef
AU  - Kavgacı, Akif
DO  - 10.5606/tgkdc.dergisi.2023.23748
PY  - 2023
JO  - Türk Göğüs Kalp Damar Cerrahisi Dergisi
VL  - 31
IS  - 1
SN  - 1301-5680
SP  - 145
EP  - 148
DB  - TRDizin
UR  - http://search/yayin/detay/1177325
ER  -